Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor von Rivera, V. M., Kreisberg, J. I., Mita, M. M., Goldston, M., Knowles, H. L., Herson, J., Rowinksy, E., Bedrosian, C. L., Tolcher, A.

Volltext

Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors von Mould, Diane R., Holford, Nicholas H. G., Schellens, Jan H. M., Beijnen, Jos H., Hutson, Paul R., Rosing, Hilde, Bokkel Huinink, Willem W., Rowinsky, Eric K., Schiller, Joan H., Russo, Mark, Ross, Graham

Volltext

506 Durable disease stabilization and antitumor activity with rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, in combination with gemcitabine: a phase I and p... von Calvo, E., Rowinksy, E.K., Tolcher, A.W., Chu, Q.S., Beeram, M., Mita, A., Mettinger, K., Knepper, M., Goetz, A.D., Patnaik, A.

Volltext